Protagonist Therapeutics (PTGX) Return on Sales (2017 - 2026)

Protagonist Therapeutics (PTGX) has 10 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.02% (down 2.0% YoY), and the FY2025 full-year result was 0.03%, down 3.0% from the prior year.
• Return on Sales rose to 0.0% in Q1 2026, from 0.06% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.01% in Q4 2023 to a low of 1.69% in Q1 2023.
• A 5-year average of 0.18% and a median of 0.06% in 2025 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales tumbled 166 bps in 2023 and jumped 169 bps in 2024, its largest moves.
• Tracing PTGX's Return on Sales over 5 years: stood at 0.07% in 2022, then jumped by 113 bps to 0.01% in 2023, then fell by 9 bps to 0.01% in 2024, then slumped by 848 bps to 0.06% in 2025, then surged by 101 bps to 0.0% in 2026.
• Business Quant data shows PTGX's Return on Sales at 0.0% in Q1 2026, 0.06% in Q4 2025, and 0.08% in Q3 2025.